Vascular calcification inhibitors and cardiovascular events in peritoneal dialysis patients

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Cardiovascular diseases (CVD) and vascular calcification (VC) are prevalent in chronic kidney disease (CKD) and peritoneal dialysis (PD) patients, increasing morbidity, mortality, and healthcare costs.
• VC risk is significantly higher in CKD patients compared to the general population.
• Understanding factors that protect against VC is crucial for this high-risk group.

Purpose of the Study:

• To provide a comprehensive overview of known calcification inhibitors.
• To describe the regulatory mechanisms of these inhibitors.
• To discuss the relationship between calcification inhibitors and VC development in PD patients.

Main Methods:

• This study is a narrative review of existing literature.
• It synthesizes information on calcification inhibitors and their roles.
• Focuses on mechanisms relevant to vascular calcification in PD.

Main Results:

• Certain proteins, including fetuin-A, osteopontin, osteoprotegerin, and bone morphogenetic protein-7, have been identified as calcification inhibitors.
• These inhibitors play a role in preventing or reducing vascular calcification.
• Their mechanisms of action and regulatory pathways are being elucidated.

Conclusions:

• Calcification inhibitors represent a promising area for understanding and potentially treating vascular calcification in PD patients.
• Further research into these proteins and their regulatory mechanisms could lead to novel therapeutic strategies.
• Targeting calcification inhibitors may help reduce cardiovascular morbidity and mortality in CKD and PD populations.